Healthcare sector | Medical Devices industry
| Price | $0.61 |
|---|---|
| Shares Outstanding | 140.0M |
| All-Time Low | $0.33 |
| 52-Week Low | $0.34 |
| Net Cash / Share | $0 |
|---|---|
| Net Current Assets / Share | $0.16 |
| Net Tangible Assets / Share | $0.26 |
| Shares Outstanding Ave Change (Annual) | 16.89% |
| Shares Δ YoY | 6.81% |
| Avg CA Burn (Annual %) | 15.41% (as of 2-20-2026) |
| Avg CA Burn (Quarterly %) | 2.49% (as of 2-20-2026) |
| Max Earning Power / Share | $0.25 |
|---|---|
| Adjusted Earning Power |
$0.09
adjustedEarningPower = (Net Income / EP_MULTIPLIER) / Shares Outstanding
|
| Non-Cash Charges to Market Cap |
1.34%
nonCashChargeToMKTCAP = Non-Cash Charges / Market Capitalization
|
| Avg EBITDA (5Y) | 1.3M (as of 2-20-2026) |
| Avg EBITDA (5Q) | 2.4M (as of 2-20-2026) |
| Avg Net Income (5Y) | -7.3M (as of 2-20-2026) |
| Avg Net Income (5Q) | -654.6K (as of 2-20-2026) |
| Dividend indicators | Value | Date |
|---|---|---|
| Current Dividend Streak | No | 2-20-2026 |
| Consecutive Years Paid | No | 2-20-2026 |
| Pays Dividend | No | 2-20-2026 |
| Last Dividend Date | 2-13-18 | |
| Income indicators | Value | Date |
|---|---|---|
| EBITDA Positive | Yes | 2-20-2026 |
| Net Income Positive | Yes | 2-20-2026 |
| Current Dividend Streak | No | 2-20-2026 |
Pick a metric to view its history table and chart.
Formula: Tangible Book Value / shares from balance statements. Includes 5 quarterly + 4 annual.
Chart plots one TBV / Share point per report date (duplicate same-date annual/quarterly rows are merged).
| Report Date | Period | TBV / Share | Tangible Book Value | Shares Used |
|---|---|---|---|---|
| 2025-09-30 | Quarterly | $0.26 | 36M ($36,021,000) | 140M (140,004,240) |
| 2025-06-30 | Quarterly | $0.24 | 33.7M ($33,708,000) | 139.3M (139,315,722) |
| 2025-03-31 | Quarterly | $0.21 | 28.7M ($28,651,000) | 139.1M (139,082,174) |
| 2024-12-31 | Quarterly | $0.20 | 27.3M ($27,305,000) | 139M (139,045,664) |
| 2024-12-31 | Annual | $0.20 | 27.3M ($27,305,000) | 139M (139,045,664) |
| 2024-09-30 | Quarterly | $0.21 | 29.6M ($29,635,000) | 138.7M (138,680,874) |
| 2023-12-31 | Annual | $0.26 | 34M ($33,962,000) | 130.2M (130,180,031) |
| 2022-12-31 | Annual | $0.28 | 30.6M ($30,622,000) | 108.9M (108,874,803) |
| 2021-12-31 | Annual | $0.31 | 27.3M ($27,278,000) | 87.1M (87,068,980) |
Revenue from income statements. Includes 4 annual.
Chart plots one annual Revenue point per report date.
| Report Date | Revenue |
|---|---|
| 2024-12-31 | 117.3M ($117,267,000) |
| 2023-12-31 | 91.3M ($91,303,000) |
| 2022-12-31 | 58M ($57,969,000) |
| 2021-12-31 | 55.3M ($55,263,000) |
Historical cash dividends per share from Yahoo ex-dividend dates.
| Date | Dividend / Share |
|---|---|
| No dividend payment history available yet | |
| Date | Shares Outstanding | Delta |
|---|---|---|
| No recent share changes | ||
Latest short-interest change: 18,020 shares (0.01% of float) | Days to cover: 0.13
| Date | Short Interest | Delta | Δ % |
|---|---|---|---|
| 2026-03-11 | 18,020 shares | -10,092 | -35.90% |
| 2026-02-26 | 28,112 shares | +7,441 | +36.00% |
| 2026-02-11 | 20,671 shares | -4,069 | -16.45% |
Volume/ratio use shares outstanding as of the event date (frozen).
| Date | Volume | Shares Outstanding | Volume / Shares | Price |
|---|---|---|---|---|
| No interesting volume events | ||||
Xtant Medical Holdings, Inc. provides regenerative medicine products and medical devices for orthopedic and neurological surgeons in the United States and internationally. The company offers OsteoSponge, a natural scaffold for cellular in-growth; OsteoSelect DBM Putty, which can be compressed into bony voids; OsteoSelect PLUS DBM Putty to deliver handling properties and ensure patient safety through validated and terminal sterilization; 3Demin, a family of allografts that maximizes osteoconductivity and the osteoinductive potential of human bone; OsteoFactor, a processed allograft that contains retained growth factors found within the endosteum layer of allograft bone; OsteoVive Plus, an aseptically processed and viable bone allograft; and nanOss products that provide osteoconductive nano-structured hydroxyapatite and an engineered extracellular matrix bioscaffold collagen carrier. It also provides sports allografts for anterior and posterior cruciate ligament repairs, anterior cruciate ligament reconstruction, and meniscal repair; milled spinal allografts for cortical bone milled to desired shapes and dimensions; and traditional allografts for orthopedics, neurology, podiatry, oral/maxillofacial, genitourinary, and plastic/reconstructive applications. In addition, the company offers cervical products comprising Spider cervical plating, Streamline OCT, and CervAlign systems; thoracolumbar products consisting of Axle-X interspinous fusion, Streamline MIS spinal fixation, Streamline TL spinal fixation, and HPS 2.0 hybrid performance systems; and Silex sacroiliac joint fusion systems. Further, it provides interbody products comprising Calix for cervical and thoracolumbar applications, Irix-C Cervical and Irix-A lumbar integrated dusion systems, and Fortilink implants; and interlaminar stabilization products, such as Coflex device for lumbar spinal stenosis; and CoFix implants for back and disc pain. Xtant Medical Holdings, Inc. is headquartered in Belgrade, Montana.